| Generic (Trade) Name | Company | Indication | Market of first launch | Primary Pharmacology |
|---|---|---|---|---|
| alvimopan (Entereg) | GlaxoSmithKline | post-operative ileus | US | OPI-M- |
| blonanserin (Lonasen) | Dainippon Sumitomo Pharma | schizophrenia | Japan | DOPA-D2- |
| C1-INH (Cinryze) | VirPharma (Lev) | prevention of hereditary angioedema | US | COM-1-S- |
| ceftobiprole medocaril (Zeftera) | Basilea Pharmaceutica | complicated skin and soft tissue infections | Canada | SY-CW- |
| ceramides, cholesterol and fatty acids (Epiceram) | Dr Reddy's | atopic dermatitis | US | NA |
| certolizumab pegol (Cimzia) | UCB | Crohn's disease | Switzerland | TNF-A- |
| clevidipine butyrate (Cleviprex) | The Medicines Company | hypertension | US | CHA-CA- |
| dabigatran etexilate (Pradaxa) | Boehringer Ingelheim | VTE prophylaxis in patients undergoing total hip or knee replacement surgery | UK | PR-SE-T-D- |
| desvenlafaxine succinate (Pristiq) | Wyeth | major depressive disorder | US | 5HTU- |
| eltrombopag olamine (Promacta) | GlaxoSmithKline | thrombocytopenia in immune thrombocytopenic purpura | US | TPO+ |
| etravirine (Intelence) | Johnson & Johnson | HIV/AIDS | US | PO-RDNA- |
| fesoterodine fumarate (Toviaz) | Pfizer | overactive bladder | UK | ACH-M- |
| fosaprepitant
dimeglumine (Emend for Injection/ Ivemend) |
Merck & Co | prevention of acute and delayed CINV | US | NK-1- |
| grass pollen vaccine (Oralair Grasses) | Stallergenes | rhinoconjunctivitis allergies to grass pollen | Germany | DESEN+ |
| icatibant (Firazyr) | Jenrini (Shire) | hereditary angioedema | Germany | BRAD-2- |
| ilaprazole (Aldenon) | Il-Yang | peptic ulcers | China | ATPP-HK- |
| lacosamide (Vimpat) | UCB | epilepsy | UK | CHA-NA-V- |
| levoleucovorin calcium (Fusilev) | Spectrum Pharmaceuticals | rescue after high-dose methotrexate therapy in osteosarcoma | US | UN |
| methylnaltrexone (Relistor) | Progenics Pharmaceuticals | opioid-induced constipation | UK | OPI-M- |
| pirfenidone (Pirespa) | Intermune | idiopathic pulmonary fibrosis | Japan | GF-FB- |
| plerixafor (Mozobil) | Genzyme | stem cell mobilisation | US | CK-CX-4- |
| recombinant human soluble thrombomodulin (Recomodulin) | Asahi Kasei Pharma | disseminated intravascular coagulation in sepsis | Japan | PR-SE-T- |
| regadenoson (Lexiscan) | CV Therapeutics | pharmacological stress agent for cardiac perfusion imaging studies | US | ADS-2-A+ |
| rilonacept (Arcalyst) | Regeneron | cryopyrin-associated periodic syndromes | US | IL-1- |
| rivaroxaban (Xarelto) | Bayer | VTE prophylaxis in patients undergoing total hip or knee replacement surgery | Canada | FA-10-AD- |
| romiplostim (Nplate) | Amgen | immune thrombocytopenic purpura | US | TPO+ |
| sevelamer carbonate (Renvela) | Genzyme | elevated phosphate levels in chronic kidney disease | US | PHATE- |
| sitafloxacin hydrate (Gracevit) | Daiichi Sankyo | bacterial infections | Japan | TO-2- |
| sugammadex sodium (Bridion) | Schering-Plough | reversal of neuromuscular block in anaesthesia | Sweden | UN |
| tafluprost (Taflotan) | Asahi Glass/Santen | glaucoma | Germany | PG-F2A+ |
| thrombin alfa (Recothrom) | ZymoGenetics | surgical bleeding control | US | PR-SE-T+ |
| ustekinumab (Stelara) | Janssen-Ortho | mild-to-moderate plaque psoriasis | Canada | IL-12- |
| New active substances first launched in 2008 - © Informa UK Ltd | ||||